Inositec AG Information

Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Inositec was acquired by Vifor Pharma in 2021.

Website	https://www.viforpharma.com
Revenue	$608000
Employees	3 (0 on RocketReach)
Founded	2015
Address	1 Technoparkstrasse, Zürich, Zurich 8005, CH
Phone	+41 44 271 07 55
Technologies	JavaScript , HTML , PHP +11 more (view full list)
Industry	Pharmaceutical Manufacturing, Business Services General, Biotechnology, Business Services, Science and Engineering, Medical, Health Care, Pharmaceutical
Keywords	Pharmaceutical Drug Development, Therapeutic Drug Development, Small Molecule Drugs, Pharmaceutical Research, Biomedical Research, Drug Development Platform, Drug Discovery Platform, Clinical Stage Drug Development, Biotechnology Innovation, Advanced Drug Delivery, New Drug Therapies, Precision Medicine, Chemical Synthesis
Competitors	Biocon, The Janssen Pharmaceutical Companies of Johnson & Johnson, Sandoz, Teva Pharmaceuticals, Novartis, Mylan Belgium, Roche, Amgen, Pfizer, Merck & Co., Inc. +46 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies